GlassScriptPhysician profile
Sidney S Curry
NPI 1063670412
$433.70
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $119 · 2021: $60.62 · 2022: $23.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $93.43 | 2019-2020 | |
| Genentech USA, INC. | $49.99 | 2019 | |
| Genzyme Corporation | $40.05 | 2019 | |
| Janssen Biotech, INC. | $36.89 | 2021 | |
| Pfizer INC. | $35.52 | 2019-2020 | |
| Biofrontera INC. | $30.64 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $24.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.88 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.04 | 2019 | |
| Lilly USA, LLC | $20.01 | 2020 | |
| Celgene Corporation | $18.90 | 2019 | |
| Dermira, INC. | $16.57 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.